CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Supportive CareWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (4)

Name (Synonyms) Correlation
drug1252 Zanubrutinib Wiki 0.71
drug313 Convalescent Plasma Transfusion Wiki 0.71
drug941 Random Donor Plasma Wiki 0.71
drug850 Placebo Wiki 0.06

Correlated MeSH Terms (5)

Name (Synonyms) Correlation
D015428 Myocardial Reperfusion Injury NIH 0.71
D015427 Reperfusion Injury NIH 0.71
D014947 Wounds and Injuries NIH 0.22
D002318 Cardiovascular Diseases NIH 0.18
D007239 Infection NIH 0.05

Correlated HPO Terms (1)

Name (Synonyms) Correlation
HP:0001626 Abnormality of the cardiovascular system HPO 0.18

There are 2 clinical trials

Clinical Trials

1 Efficacy of Convalescent Plasma Therapy in Severely Sick COVID-19 Patients: A Pilot Randomized Controlled Trial

Currently, no effective treatments are available for the COVID-19 pandemic, which is related to more than 70,000 deaths all over the world. Scientists and Researchers are working on many aspects of treatment options for the development of vaccination and medication to combat this life-threatening problem. Convalescent plasma from recovered COVID-19 patients contains antibodies against COVID-19 which may be beneficial to severely sick COVID019 infected patients. We have planned a randomized controlled trial to assess the efficacy of this therapy in COVID-19 infected sick patients. We will collect up to 500 ml Convalescent Plasma from the COVID-19 infected recovered patient after 14 days of clinical and radiological recovery with two consecutive COVID-19 negative tests by PCR. We will further test the sample from the collected plasma for COVID-19 specific antibodies and their titer. This plasma will be frozen and sent to the treating center (MAMC). 200-600 ml of convalescent plasma will be transfused to patients who fit the eligibility criteria and are randomized to the convalescent plasma group. This will be done in severely sick patients. Data will be collected for the benefit and adverse events related to convalescent plasma transfusion.

NCT04346446 COVID Drug: Convalescent Plasma Transfusion Other: Supportive Care Drug: Random Donor Plasma

Primary Outcomes

Measure: Proportion of patients remaining free of mechanical ventilation in both groups

Time: Day 7

Secondary Outcomes

Measure: Mortality in both groups

Time: Day 28

Measure: Improvement in Pa02/Fi02 ratio in both groups

Time: Day 2

Measure: Improvement in Pa02/Fi02 ratio in both groups

Time: Day 7

Measure: Improvement in SOFA score in both groups

Time: Day 2

Measure: Improvement in SOFA score in both groups

Time: Day 7

Measure: Duration of hospital Stay in both group.

Time: Day 28

Measure: Duration of Intensive Care Unit stay in both groups.

Time: Day 28

Measure: Requirements of Vasopressor in both groups.

Time: Day 28

Measure: Days free of dialysis in both groups.

Time: Day 28

2 A Phase 2, Randomized, Double Blind, Placebo-Controlled Study of Zanubrutinib Treatment in Patients Hospitalized for COVID-19 Infection and Pulmonary Distress

The primary objective of this study is to evaluate if the addition of zanubrutinib to supportive care increases the respiratory failure-free survival rate at Day 28 in participants hospitalized for Corona Virus Disease 2019 (COVID-19) and pulmonary distress.

NCT04382586 COVID-19 Pulmonary Complications COVID-19 Drug: Zanubrutinib Drug: Supportive Care Drug: Placebo
MeSH:Infection

Primary Outcomes

Description: Respiratory failure-free survival rate 28 is defined as the proportion of patients who have not had respiratory failure nor died <= 28 days from randomization.

Measure: Respiratory failure-free survival rate at day 28

Time: 28 Days

Secondary Outcomes

Measure: Median reduction in days spent on supplemental oxygen

Time: Up to 28 Days

Measure: All-cause mortality

Time: Up to 28 Days

Measure: Proportion of participants experiencing respiratory failure or death

Time: Up to 28 Days

Measure: Mechanical ventilation-free survival

Time: Up to 28 Days

Measure: Days on mechanical ventilation

Time: Up to 28 Days

Measure: Duration of hospitalization

Time: Up to 28 Days

Measure: Time to discharge

Time: Up to 28 Days

Measure: PaO2:FiO2 and/or oxygenation index

Time: Up to 28 Days

Description: This scale evaluates the safety and efficacy of investigational therapeutic agents in combination with care for the treatment of hospitalized participants suffering from COVID-19 infections on a scale of scores from 0 to 8, with higher scores indicating higher level of severity of the disease. (0 = No clinical or virological evidence of disease, and 8 = Death)

Measure: Change from Baseline to Day 14 in WHO - 8 Point Ordinal Scale

Time: Up to 28 Days

No related HPO nodes (Using clinical trials)